home / stock / pdsb / pdsb news

PDSB News and Press, PDS Biotechnology Corporation From 03/07/23

Stock Information
Company Name: PDS Biotechnology Corporation
Stock Symbol: PDSB
Market: NASDAQ
Website: pdsbiotech.com
Menu
PDSB PDSB Quote PDSB Short PDSB News PDSB Articles PDSB Message Board
Get PDSB Alerts

News, Short Squeeze, Breakout and More Instantly...
PDSB - PDS Biotech to Participate at 33rd Annual Oppenheimer Healthcare Conference

FLORHAM PARK, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that Dr. Frank Bedu-Addo, President and Chief Ex...
PDSB - Catalyst watch: General Electric, Apple, Chevron, Black Knight and Ethereum in the spotlight

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. ...

PDSB - PDS Biotech Announces the Publication of PDS0301 Study Linking Induced Changes in Immune Responses with Clinical Outcomes in International Immunopharmacology Journal

FLORHAM PARK, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced that clinical research conducted by the NCI, one o...

PDSB - PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor

FLORHAM PARK, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced the successful completion of a Type B meeting with the ...
PDSB - PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune(TM)

FLORHAM PARK, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced that new research performed in the laboratory of pr...

PDSB - PDS Biotech Announces Publication of Preclinical Infectimune(TM) Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses

FLORHAM PARK, N.J., Feb. 08, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced that preclinical studies involving Infectimune!...

PDSB - PDS Biotech Announces Abstract Accepted for Presentation at ESMO Targeted Anticancer Therapies Congress

FLORHAM PARK, N.J., Feb. 06, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that an abstract investigating the ability of...
PDSB - PDS Biotech Announces Participation in the Channelchek Takeaway Series

FLORHAM PARK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced its participation in the Channelchek Takeaway...

PDSB - PDS Biotech to Participate at the B. Riley Securities 3rd Annual Oncology Conference

FLORHAM PARK, N.J., Jan. 13, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that its management will participate in a firesid...

PDSB - PDS Biotechnology: Good Data, But I Am A Little Perplexed By Their Finances

Summary Over the last 18 months, PDS Biotechnology has continued producing some good data in HPV-associated cancers. However, I am a little perplexed by their finances. I will continue to watch this stock. PDS Biotech ( PDSB ) uses its Versammune platform combined with...
Previous 10 Next 10